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Pyrroloquinazoline is a potential privileged scaffold to produce different type of bioactivities resulting from different substitutions. Because many of the newly unveiled targets fall into the category of "undruggable" targets like transcription factors and structural proteins, [4] [5] [6] additional library members with unique structural and biological features will be in critical need. In this context, chemical library members from privileged chemical scaffolds will be highly desirable.
As initially put by Evans, 7 a privileged chemical structure is defined as a chemical scaffold with distinct and specific biological activities towards multiple unrelated biological targets. For example, benzodiazepine is a classical privileged scaffold.
Prominent members with benzodiazepine scaffold include widely used sedative drugs diazepam ( Figure 1 ) and nitrazepam. 8 These drugs bind γ-aminobutyric acid (GABA A )-receptors to potentiate the inhibitory neurotransmitter GABA's action. 9 Other members with benzodiazepine scaffold have been shown to be cholecystokinin (CCK) receptor antagonists 7, 10 (e.g. L-364,718) and apoptosis-inducing agents 11, 12 (e.g.
Bz-423) (Figure 1 ). Spirooxindole is another widely studied privileged scaffold that is present in both synthetic and naturally occurring products with drug-like properties.
These include MDM2 inhibitor MI-77301, 13 muscarinic M1 and 5-HT 2 receptor modulator pteropodine, 14 and cell cycle inhibitor spirotryprostatin A (Figure 1 ). 15, 16 Chemical libraries from privileged scaffolds thus represents rich source of chemical ligands to various biological targets. There have been excellent reviews to cover the array of privileged scaffolds. 17, 18 In this review, we will discuss the chemistry and pharmacological activities of 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (PQZ). We conclude that PQZ is emerging as a potential privileged scaffold.
Chemical Synthesis of PQZs
The synthesis of the tricyclic PQZs, 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (2) in particular, has attracted much of chemists' attention due to their wide range of pharmacological activities. For example, compound 2 potently inhibited human dihydrofolate reductase (DHFR) with K i = 1 nM. 19 One core issue of the synthetic pathways is to construct the unique tricyclic skeleton. The other focus of the syntheses is to efficiently and regioselectively introduce different substitutions to different positions on the scaffold. Therefore, diverse methods have been employed to synthesize functionalized PQZs. The first method to prepare the tricyclic ring system in 2 was reported by Ledig (Scheme 1) 20 and this method remains the method of choice with some variations. In his synthesis, 5-aminoindole hydrochloride (1) was chosen as the starting material to condense with sodium dicyanamide under reflux in 1-octanol for 13 h to directly afford PQZ 2.
To avoid the long-time heating and consequent decomposition of intermediate 3 in
Ledig's one-pot procedure, Jones et al isolated intermediate 3 and synthesized 2 through a two-step process as shown in Scheme 1. 21 With the assistance of boron trifluoride (BF 3 ) as a Lewis acid, the cyclization condition was much milder than
Ledig's method. Importantly, the overall yield of 2 was higher and formation of the alternative linear isomer was efficiently suppressed. All of these were beneficial for product isolation and purification. We later found that the currently commercially available 5-aminoindole had to be converted into its corresponding hydrochloride in order to obtain high yield of 2.
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The differential pK a s of the three nitrogen atoms (N 1 , N 3 and N 7 ) is a key factor for regioselective substitution reactions on PQZ. 22 To predict the pK a difference, Chen et al optimized the structure of 2 using quantum mechanics calculation at HF/6-31G** level of theory and calculated the Mulliken atomic charges. 23 The These compounds were synthesized by a key C-C bond ring-closure reaction of 41.
This oxidation step was effected by photocyclization with iodine under continuous UV irradiation. 
Pharmacological activities of PQZs
A wide range of biological activities have been described for various substituted and fused PQZs. The biochemical targets behind these bioactivities were better understood for some than the others. We divided this section into the biochemical targets that were modulated by different PQZs. Representative members from each class are presented to illustrate their potential medical applications.
PQZs as dihydrofolate reductase (DHFR) inhibitors
DHFR is an enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate in the presence of NADPH as the cofactor. 31 In proliferating cells, this DHFR-catalyzed reaction is the sole source to tetrahydrofolate, which is necessary for the one-carbon transfer reactions to synthesize purine, thymidine and some amino acids. Inhibition of DHFR will lead to blockage of DNA and protein synthesis, both of which are critical for the proliferating cells. Therefore, DHFR inhibitors exhibit activity against various cancers, bacterial infections and parasitic diseases. A large number of PQZs have been evaluated as inhibitors of DHFR from various species. 19 In fact, the original design of 2 was to mimic the known structural elements required for DHFR inhibition. 19, 20 These structure-activity relationship (SAR) studies showed that a large hydrophobic group appended to N 7 was optimal for DHFR inhibition. 19, 32 Therefore, the majority of structural analogs of 2 in the literature possess an N 7 -alkyl group. 19 In addition, they found that the inhibitory activity on fungal DHFR increased significantly with compounds having C 8 substituted with a small group. As one of the most potent inhibitors among these congeners, 45 ( Figure   2 ) not only exhibited potent inhibitory potency against C. albicans and human DHFR (K i s 30 pM and 0.3 pM respectively), but also efficiently protected the mice from infections caused by Pneumocystis carinii and Candida albicans. 
Anti-cancer agents
McCormack et al evaluated a series of PQZs as potential anticancer agents. 35 A benzyl group attached to N 7 was crucial to retain excellent inhibitory potency, while the non-substituted or methylated derivatives were almost three orders of magnitude less potent. 
PQZs as protease-activated receptor (PAR) antagonists
Thrombin is a plasma trypsin-like serine protease and promotes platelet activation and aggregation. 37 The cellular effect of thrombin is partially mediated by G protein-coupled protease-activated receptors (PARs). 38 Activation of PARs is initiated by the cleavage of the receptor's N-terminal exodomain by thrombin. Then the resulting new N-terminus, acting as a tethered ligand, binds to an extracellular loop of the receptor and induces transmembrane signaling. 38, 39 Among the four identified PARs (PAR1, PAR2, PAR3 and PAR4), PAR1 is critical for modulation of thrombin signalling in vascular endothelial cells. 40 Moreover, PAR1, expressed on the surface of human platelets, shows higher affinity to thrombin than PAR4. This higher affinity translates to activation of human platelets by lower concentrations of thrombin. 41, 42 Since inhibition of platelet aggregation could be a promising treatment strategy for thrombosis and restenosis, 43 there has been strong interest in developing PAR
antagonists. Researchers at then Schering-Plough initiated a HTS campaign to identify non-peptidic PAR1 antagonists. 24 From this screening, PQZ 47 ( Figure 3) was identified as a hit with an IC 50 of 300 nM. A series of related PQZs were designed and synthesized to investigate their SARs. It was found that modifications including alkylation, acylation and sulfonylation at N 7 other than benzylation significantly decreased binding activity to PAR1. Modifications at N 1 and N 3 generated compounds with variable potency. Small alkyl groups at N 3 were favoured while substitution at N 1 was generally detrimental. In the absence of a crystal structure of the complex between PAR1 and PQZs, these SAR results were rationalized by the later-developed 3D-QSAR (three-dimensional quantitative structure-activity relationship) models. 44 Among the synthesized PQZs as PAR antagonists, N 3 -cyclopropylated compounds 48 (SCH79797) and 49 (SCH203099) were the most potent analogs (Figure 3 ). 24 Both of the compounds significantly blocked the binding between PAR1 on the platelet membranes and a PAR1 peptidic agonist ha-TRAP 
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In addition to its role in blood clotting, thrombin is also an important factor to mediate myocardial ischemia/reperfusion (I/R) injury. 48 Functional inhibition of thrombin could result in a significant decrease in infarct size following I/R. 49 Based on these findings, PAR1 was hypothesized as a potential target for I/R. 50 Before or during ischemia, treatment with 48 introduced an immediate reduction of infarct size and decrease of myocardial necrosis. 50 If given after ischemia, 48 could also decrease adverse left ventricular (LV) remodelling and preserve LV function through late stage antifibrotic events. 51 Compound 48 down-regulated the downstream signalling activities of PAR1, which is a crucial initiator of tissue stiffening in cardiac fibroblasts after I/R injury. Therefore, PAR1 inhibitors could be a potential therapy to both myocardial I/R injury and postinfarction cardiomyopathy.
During a study on the fused pyrroloheterocycles, Ferlin et al reported new phenyl pyrroloquinolinones as potential antimitotic agents. 52 They also discovered that a series of 3-phenyl-pyrroloquinazolinones displayed platelet aggregation inhibitory activity. 28 Compound 50 ( Figure 3 ) exhibited the most potent antagonistic activity towards the thrombin-induced platelet aggregation among these derivatives. The comparison between 50 and other analogs showed that both alkyl groups at pyrrolic nitrogen and a methoxy group on the appendant phenyl ring attenuated inhibitory activity. Besides blocking platelet activation, 50 also affected PAR agonist-induced increase of cytosolic [Ca 2+ ] in platelets. Although these biological readouts would be consistent with antagonism of PAR, direct PAR binding data were not established. In fact, its inhibitory effect on platelet aggregation induced by PAR-independent collagen would suggest alternative mechanism of action than PAR inhibition. 28 Overall, the SAR of PQZs as PAR antagonists is distinctly different from that of DHFR inhibition.
PQZs as protein tyrosine phosphatase 1B (PTP1B) inhibitors
PTP1B is the first protein tyrosine phosphatase to be cloned. Functional studies of PTP1B provided convincing evidence that it is a negative regulator of insulin sensitivity. 53, 54 Therefore, pharmacological inhibitors of PTP1B would represent a promising strategy to develop therapeutics for type 2 diabetes (T2D). 55 Roche scientists screened their internal collection of compounds for small molecule PTP1B
inhibitors to yield a series of substituted PQZs (Figure 4) . [56] [57] [58] A large number of PQZs, most of which contained an aryl substitution at C 6 , were prepared to evaluate their PTP1B inhibitory activity. No detailed SAR studies have been published, but the IC 50 for these compounds ranged from 1.09-91.79 µM, 58 which is ~1000 fold less potent than the prototypical PQZ DHFR inhibitors. Two representative compounds 51 and 52 are shown in Figure 4 . NMR studies showed that these compounds do not directly bind to the phosphate binding pocket, suggesting a unique mechanism of action. 
Miscellaneous targets
Guan et al followed up a series of antimalarial PQZs initially prepared by Ledig 20 and identified WR227825 ( Figure 5 ), which exhibited potent antimalarial activity both in vitro and in vivo, but with high host toxicity. 25 To reduce the host toxicity, different types of substitution were introduced to the amino groups at C 1 and C 3 , such as alkyl and acyl groups. One such modified compound 53 ( Figure 5 ) not only showed excellent antimalarial activity against various clones of Plasmodium falciparum in vitro, but also good efficacy in mice and non-human primates.
Compound 53 could be rapidly deacetylated in plasma to generate WR227825 and therefore was considered as a prodrug. 59 Although it has not been established if WR227825 inhibits pfDHFR biochemically, its structure would predict it was a potent pfDHFR inhibitor and its antimalarial activity likely arose from pfDHFR inhibition.
The safety profile of 53 improved significantly compared to that of WR227825. 60 In the adult rat P. berghei infection model, the therapeutic index of 53 was 80, while that of WR227825 was only 10. The metabolism of 53 to WR227825 included three steps of sequential hydrolysis of acetamide. 59 Since the metabolic intermediates had similar activity to WR227825, the therapeutic potency of 53 was not affected by such transformations in vivo. In fact, the multiple-step metabolic process was the major reason for its decreased host toxicity to allow gradual release of toxic WR227825. presented variable anti-proliferative activity. In general, the N 1 -acylated compounds were less potent than N 3 -acylated ones. Within the series of N 3 -acylated PQZs, N 3 -arylacyl substitution was favoured. 22 Among these compounds, 54 exhibited superior activity in both of the two cell lines ( Figure 5 ). Importantly, 54 was not toxic to normal human mammary epithelial cells. The anti-proliferative activity of 54 was not due to human DHFR inhibition and its biological target(s) to mediate its selective toxicity in cancer cells remain to be identified. 22 In addition to the diverse biological activities mentioned above, other bioactivities have also been reported for PQZs (Table 1) . For example, PQZ 55 was reported to inhibit the replication of herpes simplex virus 1 (HSV-1) with IC 50 of 15 µM ( Figure   5 ). 64 PQZ 56 was shown to weakly (IC 50 ~100 µM) inhibit serum paraoxonase (PON), a calcium-dependent esterase to hydrolyze organophosphate ( Figure 5 ). 65 Other more extensively fused PQZs have also been shown to present different biological activities.
Tetracyclic pyrimido [4,5- Figure 5 ). 30 Finally, compound 2 is currently collected in the National
Institutes of Health (NIH) molecular library and has been screened more 600 times in different assays, 66 and it was found to be active as an inhibitor of dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A), DNA repair proteins Rad52
and Rad54 ( 
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MDA-MB-231 GI 50 : 1.60 ± 0.51 µM MDA-MB-468 GI 50 : 0.44 ± 0.14 µM
WR227825

